Form 4: Vor Biopharma 10% Owner Sells Over 670K Shares

Reprogrammed Interchange LLC, a 10% owner and director of Vor Biopharma, sold over 670,000 shares of common stock in late August 2025 under a pre-arranged trading plan.

Summary

• Reprogrammed Interchange LLC, identified as a Director and 10% Owner of Vor Biopharma Inc. (VOR), reported sales of common stock.
• The transactions were executed pursuant to a Rule 10b5-1(c) pre-arranged trading plan.
• On August 25, 2025, 387,346 shares of common stock were sold at a weighted average price of $2.1163 per share, with prices ranging from $2.05 to $2.215.
• Following this transaction, Reprogrammed Interchange LLC beneficially owned 38,586,755 shares.
• On August 26, 2025, an additional 284,190 shares of common stock were sold at a weighted average price of $2.0808 per share, with prices ranging from $2.06 to $2.145.
• After both reported transactions, Reprogrammed Interchange LLC's beneficial ownership stands at 38,302,565 shares.
• Reid Hoffman, also a Director and potentially deemed a beneficial owner through his shared control and indirect pecuniary interest in Reprogrammed Interchange LLC, disclaims beneficial ownership except to the extent of his pecuniary interest.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to significant insider selling by a 10% owner and director. Although the sales were pre-planned under a 10b5-1 plan, which mitigates the immediate negative signal of reactive selling, it still represents a reduction in a major insider's stake in the company.

Negatives

• A significant reduction in beneficial ownership by a 10% owner and director, Reprogrammed Interchange LLC, totaling 671,536 shares over two days.
• The sales occurred at weighted average prices of $2.1163 and $2.0808, which could be perceived as a lack of confidence in the near-term stock price by a major insider.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Reid Hoffman, a Director, may be deemed a beneficial owner of securities held by Reprogrammed Interchange LLC due to shared control and indirect pecuniary interest. He disclaims beneficial ownership except to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders may interpret the significant insider selling by a 10% owner as a potential signal of reduced confidence in the company's short-to-medium term prospects, potentially leading to downward pressure on the stock price.
• The pre-arranged nature of the sales (10b5-1 plan) might temper the immediate negative reaction compared to an unplanned sale, but the overall reduction in insider exposure remains a factor for investors to consider.

Key Dates

Recommendation

While the insider selling by Reprogrammed Interchange LLC is substantial, the disclosure that it was executed under a Rule 10b5-1 plan suggests these were pre-scheduled transactions rather than a reaction to new, adverse company developments. This mitigates the immediate 'sell' signal. However, the reduction in a significant insider's stake warrants caution. Investors should 'hold' and monitor future developments, particularly any further insider transactions or company-specific news, to assess the long-term implications of this reduced insider exposure.

Keywords

Vor Biopharma, VOR, Reprogrammed Interchange LLC, Reid Hoffman, Insider Selling, Form 4, SEC Filing, Stock Sale, 10b5-1 Plan